NCT03353428

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

Interventional Treatment of Lung Cancer (LC) With LC Specific Immune Lymphocytes (LC-CTLs)

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Shenzhen Geno-Immune Medical Institute · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the safety of lung cancer specific cytotoxic lymphocytes (LC-CTLs). The secondary objectives are to evaluate the rate of successful LC-CTLs generation in vitro and determine the anti-lung cancer efficacy.

Detailed description

Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). Worldwide in 2012, lung cancer occurred in 1.8 million people and resulted in 1.6 million deaths. Common treatments include surgery, chemotherapy, and radiotherapy. Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with specific viral antigens has proven to be effective. Here, the investigators aim to evaluate the safety and efficacy of multiple infusions of lung cancer specific cytotoxic T lymphocytes cells in patients.

Conditions

• Lung Cancer
• NSCLC

Interventions

Type	Name	Description
BIOLOGICAL	LC-CTLs	2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time

Timeline

• Start date: 2017-11-15
• Primary completion: 2019-01-01
• Completion: 2020-12-01
• First posted: 2017-11-27
• Last updated: 2018-03-27

Locations

1 site across 1 country: China